Crystallography Open Database

Result: there are 51 entries in the selection

Switch to the old layout of the page

Download all results as: list of COD numbers | list of CIF URLs | data in CSV format | archive of CIF files (ZIP)

Searching journal of publication like 'Molecular pharmaceutics' volume of publication is 12

Left arrow Left arrow First | Left arrow Previous 20 | of 3 | Next 20 Blue right arrow | Last Blue right arrow Blue right arrow | Display 5 20 50 100 200 300 500 1000 entries per page

COD ID Blue up arrow Links Formula Up arrow Space group Up arrow Cell parameters Cell volume Up arrow Bibliography
1519620 CIFC23 H29 N3 O6P 1 21 19.7456; 10.052; 12.315
90; 107.912; 90		1147.93Maguire, Courtney K.; Brunskill, Andrew P. J.
Assessment of the Stoichiometry of Multicomponent Crystals Using Only X-ray Powder Diffraction Data.
Molecular pharmaceutics, 2015, 12, 2061-2067
1519621 CIFC22 H27 N3 O6P 1 21 19.4995; 9.7624; 12.7614
90; 111.666; 90		1099.86Maguire, Courtney K.; Brunskill, Andrew P. J.
Assessment of the Stoichiometry of Multicomponent Crystals Using Only X-ray Powder Diffraction Data.
Molecular pharmaceutics, 2015, 12, 2061-2067
1520674 CIFC28 H33 N3 Na O10 Re SP 1 21/c 131.609; 10.4939; 9.2829
90; 96.146; 90		3061.5Jia, Jianhua; Cui, Mengchao; Dai, Jiapei; Liu, Boli
(99m)Tc(CO)3-Labeled Benzothiazole Derivatives Preferentially Bind Cerebrovascular Amyloid: Potential Use as Imaging Agents for Cerebral Amyloid Angiopathy.
Molecular pharmaceutics, 2015, 12, 2937-2946
1520723 CIFC22 H29 N3 O5P 1 21/c 113.212; 9.1505; 18.16
90; 105.195; 90		2118.7Braun, Doris E.; Koztecki, Lien H.; McMahon, Jennifer A.; Price, Sarah L.; Reutzel-Edens, Susan M
Navigating the Waters of Unconventional Crystalline Hydrates.
Molecular pharmaceutics, 2015, 12, 3069-3088
1520724 CIFC22 H28.46 N3 O4.73C 1 2/c 126.498; 9.6469; 20.342
90; 128.706; 90		4057.8Braun, Doris E.; Koztecki, Lien H.; McMahon, Jennifer A.; Price, Sarah L.; Reutzel-Edens, Susan M
Navigating the Waters of Unconventional Crystalline Hydrates.
Molecular pharmaceutics, 2015, 12, 3069-3088
1520725 CIFC22 H28.9 N3 O4.95C 1 2/c 126.663; 9.634; 20.863
90; 128.322; 90		4204Braun, Doris E.; Koztecki, Lien H.; McMahon, Jennifer A.; Price, Sarah L.; Reutzel-Edens, Susan M
Navigating the Waters of Unconventional Crystalline Hydrates.
Molecular pharmaceutics, 2015, 12, 3069-3088
1547408 CIFC11 H12 N4 O2 SP n a 2114.4393; 8.1764; 21.7395
90; 90; 90		2566.6Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547409 CIFC11 H12 N4 O2 SP n a 2114.4687; 8.1829; 21.8084
90; 90; 90		2582Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547410 CIFC11 H12 N4 O2 SP n a 2114.4829; 8.1938; 21.8441
90; 90; 90		2592.24Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547411 CIFC11 H12 N4 O2 SP n a 2114.4899; 8.2086; 21.9106
90; 90; 90		2606.09Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547412 CIFC11 H12 N4 O2 SP n a 2114.4902; 8.2249; 22.0106
90; 90; 90		2623.2Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547413 CIFC11 H12 N4 O2 SP n a 2114.4588; 8.18; 21.7664
90; 90; 90		2574.38Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547414 CIFC11 H12 N4 O2 SP n a 2114.4597; 8.1802; 21.7812
90; 90; 90		2576.35Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547415 CIFC11 H12 N4 O2 SP n a 2114.4638; 8.1835; 21.7953
90; 90; 90		2579.79Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547416 CIFC11 H12 N4 O2 SP n a 2114.4666; 8.1868; 21.8103
90; 90; 90		2583.11Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547417 CIFC11 H12 N4 O2 SP n a 2114.4701; 8.1889; 21.8216
90; 90; 90		2585.73Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547418 CIFC11 H12 N4 O2 SP n a 2114.4734; 8.1921; 21.8397
90; 90; 90		2589.48Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547419 CIFC11 H12 N4 O2 SP n a 2114.4763; 8.1946; 21.8522
90; 90; 90		2592.27Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547420 CIFC11 H12 N4 O2 SP n a 2114.4795; 8.1974; 21.8693
90; 90; 90		2595.76Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748
1547421 CIFC11 H12 N4 O2 SP n a 2114.4814; 8.1993; 21.8844
90; 90; 90		2598.5Anuradha R. Pallipurath; Jonathan M. Skelton; Mark R. Warren; Naghmeh Kamali; Patrick McArdle; Andrea Erxleben
Sulfamerazine: Understanding the Influence of Slip Planes in the Polymorphic Phase Transformation through X-Ray Crystallographic Studies and ab Initio Lattice Dynamics
Molecular Pharmaceutics, 2015, 12, 3735-3748

Left arrow Left arrow First | Left arrow Previous 20 | of 3 | Next 20 Blue right arrow | Last Blue right arrow Blue right arrow | Display 5 20 50 100 200 300 500 1000 entries per page

Back to the search form
Your own data is not in the COD? Deposit it, thanks!
Top of the page
All data in the COD and the database itself are dedicated to the public domain and licensed under the CC0 License . Users of the data should acknowledge the original authors of the structural data.